| 1 -0.1 (-9.09%) | 07-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.34 |
1-year : | 4.72 |
| Resists | First : | 2.86 |
Second : | 4.04 |
| Pivot price | 1.23 |
|||
| Supports | First : | 0.95 |
Second : | 0.79 |
| MAs | MA(5) : | 1.08 |
MA(20) : | 1.23 |
| MA(100) : | 2.2 |
MA(250) : | 4.04 |
|
| MACD | MACD : | -0.5  |
Signal : | -0.5 |
| %K %D | K(14,3) : | 6.2 |
D(3) : | 7 |
| RSI | RSI(14): 33.2 |
|||
| 52-week | High : | 16.68 | Low : | 0.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BJDX ] has closed above bottom band by 8.5%. Bollinger Bands are 65.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.11 - 1.12 | 1.12 - 1.13 |
| Low: | 1 - 1.01 | 1.01 - 1.02 |
| Close: | 1.09 - 1.1 | 1.1 - 1.11 |
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
Mon, 27 Jul 2026
Bluejay Diagnostics Inc (BJDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mon, 27 Jul 2026
Bluejay Diagnostics Inc (BJDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mon, 27 Jul 2026
BJDX|Bluejay Diagnostics Inc|Price:1.030|Chg%:-0.110 - TradingKey
Sun, 26 Jul 2026
Bluejay Diagnostics Inc (BJDX) Cash Flow - TradingKey
Sat, 25 Jul 2026
Bluejay Diagnostics, Inc. Revenue Breakdown – NASDAQ:BJDX - TradingView
Wed, 22 Jul 2026
Bank of America drops below 10% stake in Bluejay Diagnostics, Inc. (BJDX) - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 6 (%) |
| Held by Institutions | 25.7 (%) |
| Shares Short | 570 (K) |
| Shares Short P.Month | 177 (K) |
| EPS | -3.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -79.7 % |
| Return on Equity (ttm) | -171.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.28 |
| PEG Ratio | 0 |
| Price to Book value | 0.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|